NGL Fine Chem Ltd
NSE: NGLFINE BSE: 524774
â‚ą2901.30
(0.81%)
Tue, 13 Oct 2026, 10:37 pm
Market Cap (in Cr)1807.47
PE Ratio31.34
Dividend0.06
Health Technology
Pharmaceuticals: Major
24.5KNGL Fine Chem Analysis
dividend
- Dividends paid are thoroughly covered by earnings (14.2x coverage).
- NGL Fine-Chem only just started paying a dividend, it is too early to tell if payments are increasing.
- It is too early to tell whether NGL Fine-Chem has stable dividend payments.
- NGL Fine-Chem's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- NGL Fine-Chem's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- NGL Fine-Chem is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- NGL Fine-Chem is profitable, therefore cash runway is not a concern.
- NGL Fine-Chem is profitable, therefore cash runway is not a concern.
- Debt is well covered by operating cash flow (36.6%, greater than 20% of total debt).
- Debt is covered by short term assets, assets are 3.1x debt.
- NGL Fine-Chem's cash and other short term assets cover its long term commitments.
- The level of debt compared to net worth has been reduced over the past 5 years (47.5% vs 25.1% today).
- Interest payments on debt are well covered by earnings (EBIT is 11.6x coverage).
- NGL Fine-Chem's level of debt (25.1%) compared to net worth is satisfactory (less than 40%).
- High level of physical assets or inventory.
management
- The tenure for the NGL Fine-Chem board of directors is about average.
- Rahul's compensation has been consistent with company performance over the past year, both up more than 20%.
- Rahul's remuneration is higher than average for companies of similar size in India.
- More shares have been bought than sold by NGL Fine-Chem individual insiders in the past 3 months, but not in substantial volumes.
misc
- NGL Fine-Chem is not covered by any analysts.
- NGL Fine-Chem has significant price volatility in the past 3 months.
past
- NGL Fine-Chem's year on year earnings growth rate has been positive over the past 5 years.
- NGL Fine-Chem used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- NGL Fine-Chem's 1-year earnings growth is negative, it can't be compared to the 5-year average.
- NGL Fine-Chem's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
- NGL Fine-Chem has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
- NGL Fine-Chem's 1-year earnings growth is negative, it can't be compared to the IN Pharmaceuticals industry average.
value
- NGL Fine-Chem is good value based on earnings compared to the IN Pharmaceuticals industry average.
- BSE:524774 is up 11.8% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:524774 is up 11.8% outperforming the market in India which returned 8% over the past month.
- NGL Fine-Chem's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- NGL Fine-Chem's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
- NGL Fine-Chem is overvalued based on assets compared to the IN Pharmaceuticals industry average.
- NGL Fine-Chem is overvalued based on earnings compared to the India market.
- 524774 underperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 524774 underperformed the Market in India which returned -14.5% over the past year.
